Bourget L, Chang T M
Biochim Biophys Acta. 1986 Oct 1;883(3):432-8. doi: 10.1016/0304-4165(86)90281-3.
Microencapsulation of the enzyme phenylalanine ammonia-lyase was developed for in vivo depletion of systemic phenylalanine in phenylketonuric rats. Compared to normal rats, systemic phenylalanine blood levels in phenylketonuric rats was increased by 15-20-fold. Daily oral administration of 1 unit of phenylalanine ammonia-lyase-loaded artificial cells to phenylketonuric rats lowered the systemic phenylalanine level to 58% +/- 18% (mean + S.D.) in 7 days (P less than 0.010), while 5 units lowered the systemic phenylalanine level to 25% +/- 8%. 5 units of the immobilized enzyme lowered the systemic phenylalanine level to normal levels within 6 days. Phenylketonuric treated rats showed no signs of abnormal behavior and weight loss compared to phenylketonuric non-treated rats. The immobilized enzyme within artificial cells is therefore protected against low gastrointestinal pH and proteolytic enzymes.
开发了苯丙氨酸解氨酶的微囊化技术，用于体内降低苯丙酮尿症大鼠体内的全身性苯丙氨酸水平。与正常大鼠相比，苯丙酮尿症大鼠的全身性苯丙氨酸血液水平升高了15至20倍。每天给苯丙酮尿症大鼠口服1单位负载苯丙氨酸解氨酶的人工细胞，7天内可将全身性苯丙氨酸水平降至58%±18%（平均值±标准差）（P<0.010），而5单位则可将全身性苯丙氨酸水平降至25%±8%。5单位的固定化酶在6天内可将全身性苯丙氨酸水平降至正常水平。与未治疗的苯丙酮尿症大鼠相比，接受治疗的苯丙酮尿症大鼠没有出现异常行为和体重减轻的迹象。因此，人工细胞内的固定化酶受到保护，免受低胃肠pH值和蛋白水解酶的影响。
